Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (Enapotamab Vedotin, HuMax-AXL-ADC) in Patients With Solid Tumors

Next Previous
X
Search
Trial Profile

First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (Enapotamab Vedotin, HuMax-AXL-ADC) in Patients With Solid Tumors

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 13 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enapotamab vedotin (Primary)
  • Indications Cervical cancer; Endometrial cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Sarcoma; Solid tumours; Thyroid cancer
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Genmab

    • Most Recent Events

    • 19 Dec 2022 Planned number of patients changed from 374 to 426.
    • 03 Dec 2021 Status changed from active, no longer recruiting to completed.
    • 30 Jun 2021 Planned End Date changed from 1 Jun 2021 to 1 Dec 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top